OPTN - OptiNose, Inc.

9.6
-0.110   -1.146%

Share volume: 860,961
Last Updated: 05-20-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$9.71
-0.11
-0.01%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
43%
Profitability 25%
Dept financing 30%
Liquidity 75%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
2.35%
3 Months
80.79%
6 Months
1,667.96%
1 Year
823.08%
2 Year
742.11%
Key data
Stock price
$9.60
P/E Ratio 
0.00
DAY RANGE
$9.48 - $9.72
EPS 
-$2.56
52 WEEK RANGE
$0.32 - $9.75
52 WEEK CHANGE
$805.66
MARKET CAP 
92.363 M
YIELD 
N/A
SHARES OUTSTANDING 
10.127 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
12-31-2024
NEXT EARNINGS DATE
05-13-2025
BETA 
3.76
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
$118,331
Company detail
CEO: Peter K. Miller
Region: US
Website: optinose.com
Employees: 190
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. Onzetra Xsail, a powder EDS device, is in Phase IIIb clinical trial.

Recent news